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Antiviral therapy with direct-acting antiviral (DAA) for pa-
tients infected by hepatitis C virus (HCV) has made a remarkable 
progress, enabling more patients eligible for treatment compared 
to interferon era. Indeed, DAA treatment with high efficacy 
and safety is an important major component of global strategy 
to eliminate HCV infection until 2030, proposed by the World 
Health Organization (WHO).1 The epidemiological and clinical 
characteristics related to HCV infection largely differ among 
regions and countries. Even in a region or country, these char-
acteristics might be different between two time periods which 
are divided by introduction of DAA. Thus, it is relevant to figure 
out which characteristics are clinically significant in post-DAA 
period compared with pre-DAA period to help implement an ef-
fective program for HCV elimination.
In this issue, Nam et al.2 investigated the changing epidemio-
logical and clinical characteristics of HCV infection in South 
Korea between 2007 and 2017. A total of 2,758 patients with 
HCV viremia were prospectively enrolled at seven tertiary hos-
pitals. Apart from various data collected from medical records, a 
survey was conducted using patient questionnaire to reveal risk 
factors for HCV infection. The overall characteristics of patients 
including mean age, disease severity ranging from chronic 
hepatitis, cirrhosis to hepatocellular carcinoma (HCC) and HCV 
genotypes were not much different from those previously re-
ported.3 The major risk factors associated with HCV infection 
in South Korea were known to be multiple sexual partners, 
tattooing, history of transfusion, acupuncture and needle stick 
injuries.4 This article also confirms that multiple factors such as 
tattooing, piercing, blood transfusion and needle stick injuries 
contribute to HCV infection in South Korea.2 There was an epi-
demiological difference between males and females, showing a 
higher frequencies of intravenous drug use experiences, needle 
stick injuries and multiple sexual partners in males. Whereas 
such risk factors as history of transfusion, tattooing, piercing 
and acupuncture were more closely related to HCV infection in 
females, suggesting different risk factors by gender depend on 
the behavioral characteristics and degree of risk exposure.
Several clinical characteristics differed between pre-DAA 
(2007 to 2014) and post-DAA (2015 to 2017) period. The mean 
age of patients recently enrolled (post-DAA period) was higher 
than those enrolled at pre-DAA period (60.6 years vs 56.15 
years, p<0.001). Compared to pre-DAA period, there were more 
male patients, less patients with education above high-school 
level, more patients with HCC or cardiovascular disease in post-
DAA period. This observation might be partly explained by 
older age of patients in recent period.
Since introduction of DAA in early 2000, treatment paradigm 
of HCV infection has been rapidly and dramatically evolved. A 
higher sustained virological response (SVR) rates, shorter treat-
ment duration, better safety and tolerability resulted in higher 
treatment uptake rates at least in a special patient population.5 
In a modeling study, combination of higher SVR rates, improved 
HCV diagnosis and higher treatment uptake rates was found to 
achieve HCV elimination until 2030 in South Korea.6 Then, are 
treatment uptake rates actually increasing in Korea? In this ar-
ticle, the overall treatment uptake rates were 52.8% and 56.1% 
in pre-DAA and post-DAA period, respectively.2 The reasons 
why there is not apparent increase in the treatment uptake rates 
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in post-DAA period compared to pre-DAA period are (1) the 
years from 2015 to 2017 are relatively short and early period of 
DAA era, (2) the efficacy of DAA regimen at that period was not 
accepted to be perfect by physicians, thereby postponing initia-
tion of treatment. A subsequent study with a longer post-DAA 
duration is necessary to address this issue. Care of cascade con-
sisting of screening, diagnosis, referral and treatment is manda-
tory to have a success in HCV elimination. According to WHO 
report, the treatment initiation rates in 2017 are estimated to be 
low globally, ranging from 2.2% in African region to 12.1% in 
Eastern Mediterranean region.7 Owing to different health care 
policy and system in each country, one unified practice strategy 
to enhance treatment uptake rates cannot be applied to all re-
gions or countries. Rather, an individualized action plan based 
on each public health system might be more effective. For ex-
ample, in South Korea, the access to HCV therapy is less limited 
compared to other countries because all DAAs are reimbursed 
by national insurance system, geographical access to hospital 
is easy, and patients tend to want be treated in large-volume 
centers. The treatment uptake rates in post-DAA period in this 
article, 56.1%, seems to be overestimated because the participat-
ing institutions were tertiary hospitals. A nationwide treatment 
uptake rates would be much lower if small-volume institutions 
are included in the analysis. Therefore, a strategy considering 
this situation should be implemented in South Korea. Also, the 
issue of enhancing treatment uptake rates in South Korea is 
closed related to awareness of HCV infection by both patients 
and primary care physicians or doctors in department other 
than hepatology. Unlike in interferon era, due to short treatment 
duration, high efficacy and safety of DAA, hepatitis C became 
a disease which not only hepatologists but also gastroenterolo-
gist or primary care physician can manage. For the care cascade 
to operate effectively, government, academic society, primary 
care physicians and liver specialists need to play its own role in 
each step from screening, diagnosis, referral and to treatment. 
Approximately 89% of patients were asymptomatic at infection 
and a half of patients showed alanine aminotransferase levels 
less than 40 IU/L,2 implying that diagnosis of HCV infection is 
difficult without screening test in general population. Because 
progression of HCV infection poses a significant social and 
economic burden, and accumulated data indicate that national 
anti-HCV screening once in a lifetime for general population is 
cost-effective,8,9 government needs to present how to eliminate 
HCV infection in South Korea until 2030. Academic society and 
liver specialists might help to make a proper HCV screening 
program based on experiences and evidences. Other roles of liv-
er specialists include spreading knowledge on HCV disease into 
general physicians and managing “difficult-to-treat” patients.
Under well-organized health care system in both disease pre-
vention and national insurance system in South Korea, it is time 
to achieve fruitful epidemiological outcomes in HCV disease as 
in hepatitis B virus disease for the last a few decades.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ORCID
Do Young Kim https://orcid.org/0000-0002-8327-3439
REFERENCES
1. World Health Organization (WHO). Combating hepatitis B and C 
to reach elimination by 2030: advocacy brief [Internet]. Geneva: 
WHO; c2016 [cited 2019 Jul 10]. Available from: https://apps.who.
int/iris/handle/10665/206453.
2. Nam JY, Jang ES, Kim YS, et al. Epidemiological and clinical 
characteristics of hepatitis C virus infection in South Korea from 
2007 to 2017: a prospective multicenter cohort study. Gut Liver 
2020;14:207-217. 
3. Kim DY, Kim IH, Jeong SH, et al. A nationwide seroepidemi-
ology of hepatitis C virus infection in South Korea. Liver Int 
2013;33:586-594.
4. Sohn HS, Kim JR, Ryu SY, et al. Risk factors for hepatitis C virus 
(HCV) infection in Areas with a high prevalence of HCV in the 
Republic of Korea in 2013. Gut Liver 2016;10:126-132.
5. Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepa-
titis C virus (HCV) incidence in dutch human immunodeficiency 
virus-positive men who have sex with men after unrestricted ac-
cess to HCV therapy. Clin Infect Dis 2018;66:1360-1365. 
6. Alfaleh FZ, Nugrahini N, Matičič M, et al. Strategies to man-
age hepatitis C virus infection disease burden - volume 3. J Viral 
Hepat 2015;22 Suppl 4:42-65. 
7. World Health Organization (WHO). Global hepatitis report, 2017 
[Internet]. Geneva: WHO; c2017 [cited 2019 Jul 10]. Available 
from: https://www.who.int/hepatitis/publications/global-hepatitis-
report2017/en/.
8. Kim DY, Han KH, Jun B, et al. Estimating the cost-effectiveness of 
one-time screening and treatment for hepatitis C in Korea. PLoS 
One 2017;12:e0167770.
9. Kim KA, Chung W, Choi HY, Ki M, Jang ES, Jeong SH. Cost-effec-
tiveness and health-related outcomes of screening for hepatitis C 
in Korean population. Liver Int 2019;39:60-69.
